糖尿病肾病的精准医学方法:机遇与挑战
综述指出全球终末期肾病患病率持续上升,糖尿病是首要病因;糖尿病患者CKD进展速度与治疗反应存在个体差异,需个体化治疗。遗传检测目前对早期诊断、进展分类或疗效评估价值有限,而基于生物标志物的方法(如循环肿瘤坏死因子受体)可预测肾病进展,多标志物风险与药物反应评分有望推动从通用方案转向个体化方案。
要点
- 糖尿病是终末期肾病的首要病因,早期诊断CKD并适当干预可延缓肾功能下降。
- 糖尿病患者CKD进展速度与治疗反应个体差异大,需个体化治疗。
- 循环肿瘤坏死因子受体等炎症蛋白是肾病进展的强预测因子,多标志物评分可预测进展与长期药效。
核心结论
- 糖尿病肾病是多因素疾病,部分受遗传影响,也受环境或饮食等外源性介质影响。
- 遗传检测目前对早期诊断、进展分类或疗效评估价值有限。
- 基于生物标志物的方法(如循环肿瘤坏死因子受体)可识别高ESKD风险患者并辅助靶向治疗决策。
- 多标志物风险与药物反应评分可预测肾病进展和长期药物疗效,有望推动从通用方案转向个体化方案。
研究设计与样本
- 综述,描述糖尿病肾病精准医学的最新进展与未来研究方向。
主要发现
- 全球终末期肾病患病率持续增加,与糖尿病患者数量增长平行,糖尿病是ESKD的首要病因。
- 糖尿病患者CKD进展速度和对治疗的反应存在个体差异。
- 循环肿瘤坏死因子受体等炎症蛋白是肾病进展的强预测因子。
- 基于多生物标志物的风险和药物反应评分已开发用于预测肾病进展和长期药物疗效。
临床怎么用
- 对糖尿病患者应早期诊断CKD并适当干预,以延缓肾功能下降和预防ESKD。
- 可探索基于生物标志物的方法识别高ESKD风险患者,辅助靶向治疗决策。
- 多标志物风险与药物反应评分若应用于临床,可推动个体化治疗。
局限性
- 遗传检测目前对早期诊断、进展分类或疗效评估价值有限。
- 生物标志物研究尚需进一步验证和临床实施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The prevalence of end-stage kidney disease (ESKD) continuously increases worldwide. The increasing prevalence parallels the growth in the number of people with diabetes, which is the leading cause of ESKD. Early diagnosis of chronic kidney disease (CKD) in patients with diabetes and appropriate intervention is important to delay the progression of kidney function decline and prevent ESKD. Rate of CKD progression and response to treatment varies among patients with diabetes, highlighting the need to tailor individual treatment. In this review, we describe recent advances and areas for future studies with respect to precision medicine in diabetic kidney disease (DKD). DKD is a multi-factorial disease that is subject in part to genetic heritability, but is also influenced by various exogenous mediators, such as environmental or dietary factors. Genetic testing so far has limited utility to facilitate early diagnosis, classify progression or evaluate response to therapy. Various biomarker-based approaches are currently explored to identify patients at high risk of ESKD and to facilitate decision-making for targeted therapy. These studies have led to discovery and validation of a couple of inflammatory proteins such as circulating tumour necrosis factor receptors, which are strong predictors of kidney disease progression. Moreover, risk and drug-response scores based on multiple biomarkers are developed to predict kidney disease progression and long-term drug efficacy. These findings, if implemented in clinical practice, will pave the way to move from a one-size-fits-all to a one-fit-for-everyone approach.
引用
- Tye SC, Denig P, Heerspink HJL, et al. Precision medicine approaches for diabetic kidney disease: opportunities and challenges. Nephrol Dial Transplant. 2021. PMID: 34153985. doi:10.1093/ndt/gfab045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。